Abivax S.A.
AAVXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10,792 | $4,621 | $4,583 | $37 |
| % Growth | 133.5% | 0.8% | 12,286.5% | – |
| Cost of Goods Sold | $0 | $128 | $71 | $156 |
| Gross Profit | $10,792 | $4,493 | $4,512 | -$119 |
| % Margin | 100% | 97.2% | 98.5% | -321.6% |
| R&D Expenses | $146,532 | $103,176 | $48,725 | $47,202 |
| G&A Expenses | $32,946 | $22,390 | $7,492 | $5,580 |
| SG&A Expenses | $38,900 | $28,821 | $7,492 | $4,749 |
| Sales & Mktg Exp. | $5,954 | $6,431 | $0 | -$831 |
| Other Operating Expenses | -$1,656 | -$128 | $52 | $80 |
| Operating Expenses | $183,776 | $127,376 | $56,575 | $52,031 |
| Operating Income | -$172,984 | -$127,376 | -$56,646 | -$52,187 |
| % Margin | -1,602.9% | -2,756.5% | -1,236% | -141,045.9% |
| Other Income/Exp. Net | -$3,258 | -$24,857 | -$380 | $6,626 |
| Pre-Tax Income | -$176,242 | -$152,233 | -$74,322 | -$45,561 |
| Tax Expense | $0 | -$4,493 | -$4,476 | -$4,204 |
| Net Income | -$176,242 | -$147,740 | -$69,846 | -$41,357 |
| % Margin | -1,633.1% | -3,197.1% | -1,524% | -111,775.7% |
| EPS | -2.8 | -3.43 | -3.13 | -2.47 |
| % Growth | 18.4% | -9.6% | -26.7% | – |
| EPS Diluted | -2.8 | -3.43 | -3.13 | -2.47 |
| Weighted Avg Shares Out | 63,046 | 43,066 | 22,301 | 16,755 |
| Weighted Avg Shares Out Dil | 63,046 | 43,066 | 22,301 | 16,755 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,118 | $128 | $84 |
| Interest Expense | $4,185 | $13,826 | $3,934 | $3,558 |
| Depreciation & Amortization | $1,100 | $707 | $485 | $156 |
| EBITDA | -$171,883 | -$133,207 | -$53,315 | -$38,738 |
| % Margin | -1,592.7% | -2,882.6% | -1,163.3% | -104,697.3% |